Reaching New Heights in CNS Testing
Belay offers three proprietary CSF liquid biopsy tests to help clinicians detect and manage brain and spinal cord cancers.
Belay offers proprietary CSF liquid biopsy tests to help detect and manage primary and secondary central nervous system malignancies.
- Genomic profiling plays an essential role in diagnosis, classification, disease monitoring, treatment selection and clinical management for primary and metastatic brain and spinal cord cancers
- Current methods such as cytology and MRIs may lack sensitivity while biopsies are invasive and risky to the patient
- Belay’s three proprietary tests are designed to offer a validated, accurate, and minimally invasive alternative to support clinical decision-making.
Your partner in a higher standard of care.
At Belay Diagnostics, our mission is to serve patients and those who care for them. We develop clinically validated CSF liquid biopsy tests that give clinicians an advanced, minimally invasive method to help inform the diagnosis and management of central nervous system malignancies.
Belay offers proprietary CSF liquid biopsy tests to help detect and manage primary and secondary central nervous system malignancies.
- Genomic profiling plays an essential role in diagnosis, classification, disease monitoring, treatment selection and clinical management for primary and metastatic brain and spinal cord cancers
- Current methods such as cytology and MRIs may lack sensitivity while biopsies are invasive and risky to the patient
- Belay’s three proprietary tests are designed to offer a validated, accurate, and minimally invasive alternative to support clinical decision-making.
Your partner in a higher standard of care.
At Belay Diagnostics, our mission is to serve patients and those who care for them. We develop clinically validated CSF liquid biopsy tests that give clinicians an advanced, minimally invasive method to help inform the diagnosis and management of central nervous system malignancies.